Current Drug Target -CNS & Neurological Disorders

Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova


Neurodegenerative Pathways in Parkinsons Disease: Therapeutic Strategies

Author(s): S. M. Cardoso, P. I. Moreira, P. Agostinho, C. Pereira and C. R. Oliveira

Affiliation: Center for Neuroscience and Cell Biology and Institute of Biochemistry, Faculty of Medicine ofCoimbra, University of Coimbra, 3004-504 Coimbra, Portugal;


Parkinsons disease (PD), considered one of the major neurological disorders, is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by the presence of intraneuronal cytoplasmic inclusions called Lewy bodies. The causes for degeneration of PD neurons remain unclear, however, recent findings contributed to clarify this issue. This review will discuss the current understanding of the mechanisms underlying Parkinsons disease pathogenesis, focusing on the current and potential therapeutic strategies for human treatment.

Keywords: synuclein, neuronal circuits, oxidative stress, mitochondria, proteasome, neuroinflammation, cell death, therapeutics

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [405 - 419]
Pages: 15
DOI: 10.2174/1568007054546072
Price: $58